Virtus ETF Advisers LLC bought a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 55,444 shares of the biopharmaceutical company’s stock, valued at approximately $781,000. Virtus ETF Advisers LLC owned about 0.10% of Vanda Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in VNDA. Dimensional Fund Advisors LP increased its position in shares of Vanda Pharmaceuticals by 104.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 530,705 shares of the biopharmaceutical company’s stock valued at $13,867,000 after acquiring an additional 270,795 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Vanda Pharmaceuticals by 9.1% in the second quarter. Renaissance Technologies LLC now owns 2,798,050 shares of the biopharmaceutical company’s stock valued at $39,425,000 after acquiring an additional 233,300 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Vanda Pharmaceuticals by 40.7% in the first quarter. Acadian Asset Management LLC now owns 626,287 shares of the biopharmaceutical company’s stock valued at $11,523,000 after acquiring an additional 181,237 shares during the last quarter. Pictet Asset Management Ltd. increased its position in shares of Vanda Pharmaceuticals by 48.8% in the first quarter. Pictet Asset Management Ltd. now owns 371,800 shares of the biopharmaceutical company’s stock valued at $6,841,000 after acquiring an additional 121,900 shares during the last quarter. Finally, Federated Investors Inc. PA increased its position in shares of Vanda Pharmaceuticals by 90.3% in the first quarter. Federated Investors Inc. PA now owns 255,094 shares of the biopharmaceutical company’s stock valued at $4,693,000 after acquiring an additional 121,038 shares during the last quarter.

In other news, SVP Timothy Williams sold 2,575 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $14.69, for a total value of $37,826.75. Following the transaction, the senior vice president now owns 57,425 shares of the company’s stock, valued at $843,573.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard W. Dugan sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.85, for a total value of $222,750.00. Following the completion of the transaction, the director now directly owns 50,770 shares in the company, valued at approximately $753,934.50. The disclosure for this sale can be found here. 8.20% of the stock is owned by insiders.

NASDAQ VNDA traded down $0.06 during trading on Friday, reaching $13.59. 366,871 shares of the company’s stock were exchanged, compared to its average volume of 611,382. The business has a 50 day moving average price of $14.29 and a 200-day moving average price of $15.76. The stock has a market capitalization of $759.15 million, a P/E ratio of 27.40 and a beta of 0.39. Vanda Pharmaceuticals Inc. has a fifty-two week low of $11.83 and a fifty-two week high of $33.44.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.24. The firm had revenue of $59.06 million for the quarter, compared to the consensus estimate of $54.19 million. Vanda Pharmaceuticals had a return on equity of 10.23% and a net margin of 13.61%. The business’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 earnings per share. On average, analysts forecast that Vanda Pharmaceuticals Inc. will post 0.32 earnings per share for the current year.

VNDA has been the topic of a number of recent research reports. Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Friday, August 2nd. ValuEngine downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Stifel Nicolaus reissued a “hold” rating and set a $17.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, July 31st. Finally, Citigroup raised Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Thursday, August 1st. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Vanda Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $26.57.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: Death Cross

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.